- Home
- RBOT vs CRIS Comparison
RBOT vs CRIS Comparison
Compare RBOT & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | CRIS |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | 131 | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1M | 14.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | RBOT | CRIS |
|---|---|---|
| Price | $2.23 | $1.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $7.00 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 159.3K | 115.6K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $8.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $2.36 | $1.02 |
| 52 Week High | $18.97 | $4.50 |
Technical Indicators
Market Signals| Indicator | RBOT | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 30.74 | 40.64 |
| Support Level | $2.36 | $1.14 |
| Resistance Level | $2.58 | $1.41 |
| Average True Range (ATR) | 0.32 | 0.10 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 2.78 | 8.78 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.